RxDoctor Payments Data

John Hutto, MD

Cardiovascular Disease · Orangeburg, SCNPI 1154496560

Payments from drug & device makers

$4,231in general payments, 2019–2025

Across 280 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$582
  • Johnson & Johnson$574
  • E.r. Squibb & Sons, L.L.C.$567
  • Pfizer$455
  • Merck$273
  • Sanofi-aventis U.S. LLC$231
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,17899%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,231 in reported general payments places this provider in the 50th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$89,839
Medicare patients
886
Services billed
2,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban329$261,315
Repatha SureclickEvolocumab56$52,406
XareltoRivaroxaban63$49,125
EntrestoSacubitril/Valsartan40$40,673
FarxigaDapagliflozin Propanediol36$25,122
JardianceEmpagliflozin27$18,203
MultaqDronedarone Hcl20$15,184
Dofetilide55$7,426
Rosuvastatin Calcium189$4,176
Metoprolol Succinate354$3,731
Amlodipine Besylate363$2,990
Ranolazine ErRanolazine37$2,787
Ezetimibe71$2,180
Hydralazine Hcl128$1,586
ClopidogrelClopidogrel Bisulfate133$1,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$455$261,315329 claims
Johnson & JohnsonXarelto$574$49,12563 claims
NovartisEntresto$202$40,67340 claims
AstraZenecaFarxiga$40$25,12236 claims
Boehringer IngelheimJardiance$114$18,20327 claims
Sanofi-aventis U.S. LLCMultaq$231$15,18420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Orangeburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →